{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=GIST+Metastatic+Cancer", "query": { "condition": "GIST Metastatic Cancer" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 71, "total_pages": 8, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=GIST+Metastatic+Cancer&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-10T19:07:59.905Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00004910", "title": "Endoscopic Placement of Metal Stents in Treating Patients With Cancer- Related Duodenal Obstruction", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Colorectal Cancer", "Constipation, Impaction, and Bowel Obstruction", "Extrahepatic Bile Duct Cancer", "Gastric Cancer", "Gastrointestinal Carcinoid Tumor", "Gastrointestinal Stromal Tumor", "Pancreatic Cancer", "Quality of Life", "Small Intestine Cancer" ], "interventions": [ { "name": "bowel obstruction management", "type": "PROCEDURE" }, { "name": "quality-of-life assessment", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2000-01", "completion_date": "2003-02", "has_results": false, "last_update_posted_date": "2012-06-06", "last_synced_at": "2026-06-10T19:07:59.905Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004910" }, { "nct_id": "NCT01735955", "title": "Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Chronic Myelogenous Leukemia (CML)", "Metastatic Gastrointestinal Stromal Tumors (GIST)", "Acute Lymphoblastic Leukemia (ALL)", "Receptor Tyrosine Kinase (KIT) Mutated Melanoma" ], "interventions": [ { "name": "Nilotinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 57, "start_date": "2013-03-29", "completion_date": "2023-07-07", "has_results": true, "last_update_posted_date": "2024-02-08", "last_synced_at": "2026-06-10T19:07:59.905Z", "location_count": 2, "location_summary": "Albany, New York • Houston, Texas", "locations": [ { "city": "Albany", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01735955" }, { "nct_id": "NCT00087191", "title": "EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Advanced Adult Primary Liver Cancer", "Carcinoma of the Appendix", "Fallopian Tube Cancer", "Gastrointestinal Stromal Tumor", "Localized Extrahepatic Bile Duct Cancer", "Localized Gallbladder Cancer", "Localized Gastrointestinal Carcinoid Tumor", "Localized Resectable Adult Primary Liver Cancer", "Localized Unresectable Adult Primary Liver Cancer", "Metastatic Gastrointestinal Carcinoid Tumor", "Ovarian Sarcoma", "Ovarian Stromal Cancer", "Primary Peritoneal Cavity Cancer", "Recurrent Adult Primary Liver Cancer", "Recurrent Adult Soft Tissue Sarcoma", "Recurrent Colon Cancer", "Recurrent Extrahepatic Bile Duct Cancer", "Recurrent Gallbladder Cancer", "Recurrent Gastric Cancer", "Recurrent Gastrointestinal Carcinoid Tumor", "Recurrent Non-small Cell Lung Cancer", "Recurrent Ovarian Epithelial Cancer", "Recurrent Ovarian Germ Cell Tumor", "Recurrent Pancreatic Cancer", "Recurrent Rectal Cancer", "Recurrent Small Intestine Cancer", "Recurrent Uterine Sarcoma", "Regional Gastrointestinal Carcinoid Tumor", "Small Intestine Adenocarcinoma", "Small Intestine Leiomyosarcoma", "Small Intestine Lymphoma", "Stage 0 Non-small Cell Lung Cancer", "Stage I Adult Soft Tissue Sarcoma", "Stage I Colon Cancer", "Stage I Gastric Cancer", "Stage I Non-small Cell Lung Cancer", "Stage I Ovarian Epithelial Cancer", "Stage I Ovarian Germ Cell Tumor", "Stage I Pancreatic Cancer", "Stage I Rectal Cancer", "Stage I Uterine Sarcoma", "Stage II Adult Soft Tissue Sarcoma", "Stage II Colon Cancer", "Stage II Gastric Cancer", "Stage II Non-small Cell Lung Cancer", "Stage II Ovarian Epithelial Cancer", "Stage II Ovarian Germ Cell Tumor", "Stage II Pancreatic Cancer", "Stage II Rectal Cancer", "Stage II Uterine Sarcoma", "Stage III Adult Soft Tissue Sarcoma", "Stage III Colon Cancer", "Stage III Gastric Cancer", "Stage III Ovarian Epithelial Cancer", "Stage III Ovarian Germ Cell Tumor", "Stage III Pancreatic Cancer", "Stage III Rectal Cancer", "Stage III Uterine Sarcoma", "Stage IIIA Non-small Cell Lung Cancer", "Stage IIIB Non-small Cell Lung Cancer", "Stage IV Adult Soft Tissue Sarcoma", "Stage IV Colon Cancer", "Stage IV Gastric Cancer", "Stage IV Non-small Cell Lung Cancer", "Stage IV Ovarian Epithelial Cancer", "Stage IV Ovarian Germ Cell Tumor", "Stage IV Pancreatic Cancer", "Stage IV Rectal Cancer", "Stage IV Uterine Sarcoma", "Unresectable Extrahepatic Bile Duct Cancer", "Unresectable Gallbladder Cancer" ], "interventions": [ { "name": "EF5", "type": "DRUG" }, { "name": "motexafin lutetium", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2004-05", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-16", "last_synced_at": "2026-06-10T19:07:59.905Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00087191" }, { "nct_id": "NCT03465722", "title": "(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "GIST" ], "interventions": [ { "name": "avapritinib", "type": "DRUG" }, { "name": "regorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Blueprint Medicines Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 476, "start_date": "2018-03-26", "completion_date": "2021-09-15", "has_results": true, "last_update_posted_date": "2022-10-06", "last_synced_at": "2026-06-10T19:07:59.905Z", "location_count": 30, "location_summary": "Phoenix, Arizona • Santa Monica, California • Aurora, Colorado + 26 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Santa Monica", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Boulder", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03465722" }, { "nct_id": "NCT02164240", "title": "Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable GIST", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Gastrointestinal Stromal Tumor" ], "interventions": [ { "name": "Sunitinib", "type": "DRUG" }, { "name": "Regorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2014-07", "completion_date": "2021-05", "has_results": true, "last_update_posted_date": "2021-06-14", "last_synced_at": "2026-06-10T19:07:59.905Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02164240" }, { "nct_id": "NCT00375245", "title": "Rapamycin With Grapefruit Juice for Advanced Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Tumors", "Neoplasm Metastasis" ], "interventions": [ { "name": "Rapamycin (sirolimus)", "type": "DRUG" }, { "name": "Grapefruit Juice", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2006-09", "completion_date": "2012-05", "has_results": false, "last_update_posted_date": "2014-01-17", "last_synced_at": "2026-06-10T19:07:59.905Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00375245" }, { "nct_id": "NCT00397384", "title": "Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adenocarcinoma of the Colon", "Adenocarcinoma of the Rectum", "Advanced Adult Primary Liver Cancer", "Carcinoma of the Appendix", "Gastrointestinal Stromal Tumor", "Metastatic Gastrointestinal Carcinoid Tumor", "Metastatic Squamous Neck Cancer With Occult Primary", "Recurrent Adenoid Cystic Carcinoma of the Oral Cavity", "Recurrent Adult Primary Liver Cancer", "Recurrent Anal Cancer", "Recurrent Basal Cell Carcinoma of the Lip", "Recurrent Colon Cancer", "Recurrent Esophageal Cancer", "Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Recurrent Extrahepatic Bile Duct Cancer", "Recurrent Gallbladder Cancer", "Recurrent Gastric Cancer", "Recurrent Gastrointestinal Carcinoid Tumor", "Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Recurrent Lymphoepithelioma of the Nasopharynx", "Recurrent Lymphoepithelioma of the Oropharynx", "Recurrent Metastatic Squamous Neck Cancer With Occult Primary", "Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Recurrent Mucoepidermoid Carcinoma of the Oral Cavity", "Recurrent Non-small Cell Lung Cancer", "Recurrent Pancreatic Cancer", "Recurrent Rectal Cancer", "Recurrent Salivary Gland Cancer", "Recurrent Small Intestine Cancer", "Recurrent Squamous Cell Carcinoma of the Hypopharynx", "Recurrent Squamous Cell Carcinoma of the Larynx", "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity", "Recurrent Squamous Cell Carcinoma of the Nasopharynx", "Recurrent Squamous Cell Carcinoma of the Oropharynx", "Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Recurrent Verrucous Carcinoma of the Larynx", "Recurrent Verrucous Carcinoma of the Oral Cavity", "Small Intestine Adenocarcinoma", "Small Intestine Leiomyosarcoma", "Small Intestine Lymphoma", "Stage IV Adenoid Cystic Carcinoma of the Oral Cavity", "Stage IV Anal Cancer", "Stage IV Basal Cell Carcinoma of the Lip", "Stage IV Colon Cancer", "Stage IV Esophageal Cancer", "Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Stage IV Gastric Cancer", "Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Stage IV Lymphoepithelioma of the Nasopharynx", "Stage IV Lymphoepithelioma of the Oropharynx", "Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Stage IV Mucoepidermoid Carcinoma of the Oral Cavity", "Stage IV Non-small Cell Lung Cancer", "Stage IV Pancreatic Cancer", "Stage IV Rectal Cancer", "Stage IV Salivary Gland Cancer", "Stage IV Squamous Cell Carcinoma of the Hypopharynx", "Stage IV Squamous Cell Carcinoma of the Larynx", "Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IV Squamous Cell Carcinoma of the Nasopharynx", "Stage IV Squamous Cell Carcinoma of the Oropharynx", "Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage IV Verrucous Carcinoma of the Larynx", "Stage IV Verrucous Carcinoma of the Oral Cavity", "Tongue Cancer", "Unresectable Extrahepatic Bile Duct Cancer", "Unresectable Gallbladder Cancer" ], "interventions": [ { "name": "cetuximab", "type": "DRUG" }, { "name": "erlotinib hydrochloride", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2007-01", "completion_date": "2013-06", "has_results": false, "last_update_posted_date": "2015-09-30", "last_synced_at": "2026-06-10T19:07:59.905Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00397384" }, { "nct_id": "NCT00069940", "title": "Vaccine Therapy and Sargramostim in Treating Patients With Sarcoma or Brain Tumor", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain and Central Nervous System Tumors", "Gastrointestinal Stromal Tumor", "Sarcoma" ], "interventions": [ { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "telomerase: 540-548 peptide vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": null, "start_date": "2000-12", "completion_date": "2008-08", "has_results": false, "last_update_posted_date": "2010-12-28", "last_synced_at": "2026-06-10T19:07:59.905Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00069940" }, { "nct_id": "NCT06948955", "title": "Expanded Access to Bezuclastinib to be Coadministered With Sunitinib for Patients With Gastrointestinal Stromal Tumors", "overall_status": "AVAILABLE", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors" ], "interventions": [ { "name": "Bezuclastinib", "type": "DRUG" }, { "name": "Sunitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cogent Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2026-05-28", "last_synced_at": "2026-06-10T19:07:59.905Z", "location_count": 19, "location_summary": "Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 14 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT06948955" }, { "nct_id": "NCT02401815", "title": "CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Gastrointestinal Stromal Tumors" ], "interventions": [ { "name": "CGT9486", "type": "DRUG" }, { "name": "Pexidartinib", "type": "DRUG" }, { "name": "Sunitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cogent Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 51, "start_date": "2015-03-06", "completion_date": "2020-05-11", "has_results": true, "last_update_posted_date": "2025-02-14", "last_synced_at": "2026-06-10T19:07:59.905Z", "location_count": 6, "location_summary": "Miami, Florida • Boston, Massachusetts • Ann Arbor, Michigan + 3 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Detroit", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02401815" } ] }